Regeneron Pharma (REGN) PT Raised to $440 at Oppenheimer on Q2 Report; 'Eylea Static Decreasing, 2H18 Product Launches'
Tweet Send to a Friend
Oppenheimer raised its price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $410.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
